Table 3.
Effects of chronic GSK2181236A or BAY 60-4552 treatment on vasoactivity of SHR-SP isolated aorta.
| Treatment group | Phenylephrine |
Carbachol |
Sodium nitroprusside |
|||
|---|---|---|---|---|---|---|
| EC50 (nM) | Emax (% KCl) | EC50 (nM) | Emax (% reversal of PE tone) | EC50 (nM) | Emax (% reversal of PE tone) | |
| ND (n = 14) | 67 ± 6 | 90 ± 4 | 119 ± 15 | 85 ± 3*** | 5 ± 1** | 108 ± 4 |
| HSFD (n = 8) | 72 ± 11 | 83 ± 10 | 260 ± 74 | 47 ± 11 | 16 ± 3 | 103 ± 9 |
| HSFD + BAY 60-4552 (0.3 mg/kg; n = 6) | 52 ± 7 | 88 ± 6 | 460 ± 83 | 54 ± 6 | 25 ± 7 | 98 ± 5 |
| HSFD + BAY 60-4552 (3 mg/kg; n = 9) | 52 ± 8 | 89 ± 7 | 328 ± 41 | 67 ± 6 | 26 ± 10 | 112 ± 3 |
| HSFD + GSK2181236A (0.1 mg/kg; n = 4) | 46 ± 12 | 93 ± 8 | 407 ± 158 | 48 ± 14 | 26 ± 15 | 111 ± 3 |
| HSFD + GSK2181236A (1 mg/kg; n = 9) | 76 ± 16 | 91 ± 8 | 385 ± 89 | 59 ± 4 | 19 ± 5 | 100 ± 2 |
All values are expressed as mean ± SEM. Emax values are expressed as percent reversal of phenylephrine (PE)-induced tone except for phenylephrine where values are expressed as percent contractile response to 60 mM KCl. Statistical comparisons of both pEC50 and Emax values were performed using ANOVA analysis with a Dunnett’s post-test where **P < 0.01 and ***P < 0.001 vs. HSFD control SHR-SP.